InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery
Teams will work together by leveraging InveniAI’s technology platform to identify, evaluate, and optimize novel targets across Ono’s diseases of interest Ono […]
InveniAI’s AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development
– Powered by GPT-4, ChatAlphaMeld enables user interaction across functional stakeholders to automate hypothesis generation and prioritization. Integrated into the AlphaMeld workflow, […]
InveniAI and Kyowa Kirin Announce Achievement of Milestone in Research Collaboration
– Collaboration poised to exploit synergistic drug discovery and development engine to enable innovation at scale by InveniAI and validation of prioritized […]
InveniAI to Participate in the Truist Securities Life Sciences AI Symposium – Biotech & Tools
GUILFORD, Conn. USA, February 24, 2022, InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug […]
InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas
– Collaboration enables Kyowa Kirin’s R&D team to access InveniAI’s data-driven discovery platform in expanded therapeutic areas – InveniAI’s AlphaMeld® platform to provide […]
InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates
– Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD (often referred to as ASC, apoptosis-associated speck-like protein containing CARD) triggers milestone […]
Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery Collaboration
– Collaboration to create transformative therapeutics for immune diseases by combining InveniAI’s validated AI-based platform, AlphaMeld®, with Sosei Heptares’ GPCR Structure-based Drug […]
InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for […]
InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration
Teams will work together by leveraging InveniAI’s technology to identify, evaluate, and optimize novel targets for drug discovery Shionogi will synthesize and […]
InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration
Expansion of existing collaboration will leverage InveniAI® technology to identify, evaluate, and optimize novel targets for Kyowa Kirin’s antibody technology Kyowa Kirin will […]
InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways
Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI’s […]
InveniAI Enters Strategic Artificial Intelligence (AI) and Machine Learning (ML) Focused Collaboration with GlaxoSmithKline Consumer Healthcare
Three-year strategic collaboration to leverage InveniAI’s AI- and ML-powered Platform, AlphaMeld® after a successful proof-of-value collaboration AlphaMeld® will capture consumer-specific innovation for both internal […]